CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
OPERATING EXPENSES
General and administrative	$ 641	$ 543
Research and development	1,039	1,041
Total operating expenses	1,680	1,584
Interest and other expenses (income), net	111	81
Loss from operations before taxes	1,791	1,665
Income tax benefit	(36)	(56)
Net Loss	1,755	1,609
Less: Net Loss attributable to the noncontrolling interest	0	(946)
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 1,755	$ 663
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share)	$ 0.04	$ 0.02
Basic and diluted shares outstanding (in shares)	47,173	40,885